- Boom! Novartis is partnering with Qualcomm to invest up to $100 million in "beyond the pill"? technologies and services. Beyond the Pill just got a whole lot realer.
- In addition to its investment deal with Novartis, Qualcomm also cut deals with Walgreens and Novartis to use its wireless platform for connected device applications ? in the case of Novartis, for a mobile-based clinical trials program.
- Google Glass seems to be finished as a mass-market consumer product, but its proven utility in surgeries suggests a bright, if more niche, future under the ex-chief of Nest.
- Wince-enducing critique of consumer marketing and, in particular, consumer marketing of Tecfidera by a sharp-penned patient: ?Medicine aside, there was just no chemistry in my attempt to have a personal relationship with my drug company.?
- ?How technology will eat medicine?
- ?Dr. Eric Topol looks at the emerging role of smartphones, apps, aggregators, wearables, remote care and whatnot in healthcare and concludes that an age of ?doctorless medicine? may be on the horizon. His wakeup call was when a patient emailed him an ECG, having diagnosed their atrial fibrillation with an app, under the subject header ?I?m in atrial fib, now what do I do??
- Hot on the heels of their deal with Genentech, 23andMe announced that Pfizer is expanding a partnership that gave them access to data on 10,000 IBS patients to include 5,000 lupus patients.